KR20140080779A - A Bio Probe for Detecting Porcine Reproductive and Respiratory Syndrome Virus and Method for Diagnosing PRRSV Using the Same - Google Patents

Abstract

The present invention provides a bio probe for detecting a porcine reproductive and respiratory syndrome (PRRS) virus, comprising: (a) nanomaterials; (b) an antibody specifically combined with an antigen of a PRRS virus, which is covalently linked to the surface of the nanomaterials; and (c) a glass fiber which is a solid substrate having a surface modified by the antibody combined nanomaterials. The present invention also provides a method for diagnosing PRRS virus by using the bio probe. According to the present invention, the existence and infection of PRRS virus can be rapidly determined within 10 minutes using a small amount of sample.

Description

Technical Field [0001] The present invention relates to a bioprobe for detecting viruses of the genital respiratory syndrome of a pig, and a method for diagnosing porcine reproductive and respiratory syndrome virus using the same.

The present invention relates to a bio-probe for detecting virus in the genital respiratory syndrome of a pig, and a method for diagnosing porcine respiratory syndrome virus using the same.

Agglutination is an antigen-antibody reaction, a kind of immune reaction, which means aggregation between particles. It is not only immunological studies but also serological diagnosis, determination of blood type, determination of deadlock in blood transfusion, determination of bacteria in microbiology It is used widely to illuminate. On the other hand, an aggregate refers to a state in which the antigen-antibody binds to each other to increase its volume. Typical examples of immunoassays are Radioimmunoassay (RIA), Enzyme immunoassay (EIA), Particle Agglutination Immunoassay and Counting Immunoassay. However, RIA and EIA require separation of B (bound form) / F (free form) after antigen-antibody reaction and require much time and labor until analysis result is obtained.

Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.

The present inventors have sought to develop a bioprobe capable of analyzing the presence of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in a sample within a short period of time. As a result, it has been confirmed that the presence of PRRSV in the sample can be determined easily and accurately in a short time when a bioprobe is prepared by binding an antibody specific to an antigen of PRRSV to the surface of a nanomaterial and modifying the antibody to the surface of the glass fiber, Thereby completing the present invention.

Accordingly, it is an object of the present invention to provide a bioprobe for PRRSV detection.

It is another object of the present invention to provide a PRRSV diagnostic method using the above-mentioned bio-probe.

Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention and claims.

According to another aspect of the present invention, the present invention provides a bioprobe for detecting porcine reproductive / respiratory syndrome virus comprising:

(a) a nanomaterial;

(b) an antibody that specifically binds to an antigen of a porcine reproductive and respiratory syndrome virus covalently linked to the surface of the nanomaterial; And

(c) glass fiber as a solid substrate whose surface is modified with the nanomaterial to which the antibody is bound.

The present inventors have sought to develop a bioprobe capable of analyzing the presence or absence of a pathogen in a sample within a short time. As a result, it was confirmed that the presence of a pathogen in a sample can be easily and accurately determined in a short time when a bioprobe is prepared by binding an antibody specific to an antigen of PRRSV to the surface of a nanomaterial and modifying it to a glass fiber surface.

According to a preferred embodiment of the present invention, the porcine reproductive and respiratory syndrome virus which can be detected from the bioprobe of the present invention is an EU type (European type) or a US type (American type), and most preferably, a porcine reproductive / respiratory syndrome virus is a US type to be.

The bioprobes of the present invention can be prepared by (i) linking an antibody specifically binding to an antigen of PRRSV to the surface of a nanomaterial by a covalent bond, and (ii) contacting the nanomaterial bound to the antibody with a glass fiber surface Lt; / RTI >

First, the nanomaterial modified with a carboxyl group (COOH) is reacted with an antibody that specifically binds to an antigen of PRRSV to prepare the nanomaterial to which the antibody is bound. The nanomaterial used in the present invention is preferably polystyrene nanoparticles, preferably 1-500 nm, more preferably 20-300 nm, even more preferably 40-200 nm, even more preferably 60- 150 nm, most preferably 100-130 nm.

In order to increase the stability of the nanomaterial to which the antibody binds, the nanomaterial bound with the antibody is bound to the surface of the glass fiber as a solid substrate. The glass fibers used in the present invention include various glass fibers known in the art. It is preferably a borosilicate glass fiber. The shape and size of the glass fiber used in the present invention are not particularly limited. Preferably a circular shape, and has a diameter of 2-100 mm. The step of binding the antibody-bound nanomaterial to the surface of the glass fiber may be carried out by an adsorption method. Preferably, the adsorption can be carried out by mixing the sugar and the surfactant with the nanomaterial to which the antibody is bound, applying it to the surface of the glass fiber, and then drying. The drying is preferably carried out at 50-60 DEG C for 10-90 minutes.

The sugar used in the present invention includes various sugars known in the art. The sugar used in the present invention is preferably selected from sucrose, fructose, glucose, erythritol, maltitol, lactitol, sorbitol, mannitol, xylitol, D-tagatose, trehalose, galactose, rhamnose, cyclodextrin, , Inositol, isotrehalose, neotrehalose, palatinose, isomaltulose, lactose, mannose, isose, lactose, maltose, maltose, , Erythrodose, deoxyribose, gululose, aidose, talos, erythroerose, xylulose, psicose, turanose, cellobiose, glucosamine, mannosamine, fucose, glucuronic acid, gluconic acid , Gluco-lactone, aveoxose, galactosamine, xylo-oligosaccharides, gentio-oligosaccharides, galacto-oligosaccharides, sorbos, nigero-oligosaccharides, fructooligosaccharides, maltotetraol, Lactose, malto-oligosaccharide, lactulose, melibiose, raffinose, rhamnose and ribose, preferably sucrose, maltose and trehalose, most preferably sucrose and trehalose.

As the surfactant used in the present invention, any of those known in the art can be used, and for example, anionic surfactant, cationic surfactant, amphoteric surfactant and nonionic surfactant can be used, A surfactant and a nonionic surfactant are used. Specific examples of anionic surfactants include alkyl acyl glutamates, alkyl phosphates, alkyl lactylates, dialkyl phosphates and trialkyl phosphates. Specific examples of nonionic surfactants include alkoxylated alkyl ethers, alkoxylated alkyl esters, alkyl polyglycosides, polyglyceryl esters, polysorbates and sugar esters. More preferably a nonionic surfactant is used, and most preferably Tween-20 and Triton X-100 are used.

The term " antigen " used in expressing an antibody in the present invention refers to a substance derived from the PRRSV described above and stimulating the immune system to induce a specific immune response in a living body. In the present invention, the term " immunogen "). The types of antigenic substances are very diverse, and if they are foreign to the individual, in principle they are all recognized as antigens. Proteins, polysaccharides, nucleic acids, lipids, and complexes thereof are called natural antigens. In addition, chemically synthesized substances can stimulate the immune system by binding to proteins (carriers) and the like. These are called haptens (adhesives) or artificial antigens.

In the present invention, the antigen is preferably a PRRSV-derived antigen, more preferably a NP (nucleocapsid protein) antigen of PRRSV, and most preferably a PRRSV NP antigen having an amino acid sequence of SEQ ID No. 2.

The term " antibody ", as used herein, is a specific antibody to an PRRSV-derived antigen, specifically binding to PRRSV-derived antigenic proteins, and includes antigen-binding fragments of antibody molecules as well as complete antibody forms.

A complete antibody is a structure having two full-length light chains and two full-length heavy chains, each light chain linked by a disulfide bond with a heavy chain. The heavy chain constant region has gamma (gamma), mu (mu), alpha (alpha), delta (delta) and epsilon (epsilon) types and subclasses gamma 1 (gamma 1), gamma 2 ), Gamma 4 (gamma 4), alpha 1 (alpha 1) and alpha 2 (alpha 2). The constant region of the light chain has the kappa and lambda types (Cellular and Molecular Immunology, Wonsiewicz, MJ, Ed., Chapter 45, pp. 41-50, WB Saunders Co. Philadelphia, PA (1991); Nisonoff, A., Introduction to Molecular Immunology, 2nd Ed., Chapter 4, pp. 45-65, Sinauer Associates, Inc., Sunderland, MA (1984)).

An antigen binding fragment of an antibody molecule means a fragment having an antigen binding function and includes Fab, F (ab ') 2, F (ab') ₂ , Fv and the like. Fabs in the antibody fragment have one antigen-binding site in a structure having a variable region of a light chain and a heavy chain, a constant region of a light chain, and a first constant region (C _H1 ) of a heavy chain. Fab 'differs from Fab in that it has a hinge region that contains at least one cysteine residue at the C-terminus of the heavy chain C _H1 domain. The F (ab ') ₂ antibody is produced when the cysteine residue of the hinge region of the Fab' forms a disulfide bond. Recombinant techniques for producing Fv fragments with minimal antibody fragments having only heavy chain variable regions and light chain variable regions are described in PCT International Publication Nos. WO 88/10649, WO 88/106630, WO 88/07085, WO 88/07086, WO 88/09344. The double-chain Fv is a non-covalent bond, and the variable region of the heavy chain and the light chain variable region are connected to each other. The single-chain Fv generally shares the variable region of the heavy chain and the variable region of the short chain through the peptide linker Or directly connected at the C-terminus to form a dimer-like structure like the double-stranded Fv. Such an antibody fragment can be obtained using a protein hydrolyzing enzyme (for example, a Fab can be obtained by restriction of the whole antibody to papain, and F (ab ') ₂ fragment can be obtained by cleavage with pepsin) Can be produced through recombinant DNA technology.

In the present invention, the antibody is preferably in the form of a Fab or a complete antibody form. In addition, the heavy chain constant region may be selected from any one of gamma (gamma), mu (mu), alpha (alpha), delta (delta) or epsilon (epsilon).

As used herein, the term " heavy chain " refers to a variable region domain V _H comprising an amino acid sequence having a sufficient variable region sequence to confer specificity to an antigen, and a variable region domain V _H comprising three constant region domains C _H1 , C _H2 and C _H3 Quot; means both the heavy chain and the fragment thereof. As used herein, the term " light chain " also refers to both the full length light chain and its fragments, including the variable region domain V _L and the constant region domain C _L comprising the amino acid sequence with sufficient variable region sequence to confer specificity to the antigen do.

The antibody or antigen-binding fragment thereof of the present invention may include a variant of the amino acid sequence within a range that can specifically recognize the antigen protein. For example, the amino acid sequence of an antibody may be altered to improve the binding affinity and / or other biological properties of the antibody. Such modifications include, for example, deletion, insertion and / or substitution of the amino acid sequence residues of the antibody.

Such amino acid variations are made based on the relative similarity of the amino acid side chain substituents, such as hydrophobicity, hydrophilicity, charge, size, and the like. By analysis of the size, shape and type of amino acid side chain substituents, arginine, lysine and histidine are both positively charged residues; Alanine, glycine and serine have similar sizes; Phenylalanine, tryptophan and tyrosine have similar shapes. Thus, based on these considerations, arginine, lysine and histidine; Alanine, glycine and serine; And phenylalanine, tryptophan and tyrosine are biologically functional equivalents.

In introducing the mutation, the hydrophobic index of the amino acid can be considered. Each amino acid is assigned a hydrophobic index according to its hydrophobicity and charge: isoruicin (+4.5); Valine (+4.2); Leucine (+3.8); Phenylalanine (+2.8); Cysteine / cysteine (+2.5); Methionine (+1.9); Alanine (+1.8); Glycine (-0.4); Threonine (-0.7); Serine (-0.8); Tryptophan (-0.9); Tyrosine (-1.3); Proline (-1.6); Histidine (-3.2); Glutamate (-3.5); Glutamine (-3.5); Aspartate (-3.5); Asparagine (-3.5); Lysine (-3.9); And arginine (-4.5).

The hydrophobic amino acid index is very important in imparting the interactive biological function of proteins. It is known that substitution with an amino acid having a similar hydrophobicity index can retain similar biological activities. When a mutation is introduced with reference to a hydrophobic index, substitution is made between amino acids showing a hydrophobic index difference preferably within ± 2, more preferably within ± 1, even more preferably within ± 0.5.

On the other hand, it is also well known that the substitution between amino acids having similar hydrophilicity values leads to proteins with homogeneous biological activity. As disclosed in U.S. Patent No. 4,554,101, the following hydrophilicity values are assigned to each amino acid residue: arginine (+3.0); Lysine (+3.0); Aspartate (+ 3.0 ± 1); Glutamate (+ 3.0 ± 1); Serine (+0.3); Asparagine (+0.2); Glutamine (+0.2); Glycine (0); Threonine (-0.4); Proline (-0.5 ± 1); Alanine (-0.5); Histidine (-0.5); Cysteine (-1.0); Methionine (-1.3); Valine (-1.5); Leucine (-1.8); Isoru Isin (-1.8); Tyrosine (-2.3); Phenylalanine (-2.5); Tryptophan (-3.4).

When a mutation is introduced with reference to the hydrophilicity value, the amino acid is substituted preferably within ± 2, more preferably within ± 1, even more preferably within ± 0.5.

Amino acid exchange in proteins that do not globally alter the activity of the molecule is known in the art (H. Neurath, R. L. Hill, The Proteins, Academic Press, New York, 1979). The most commonly occurring exchanges involve amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu and Asp / Gly.

The antibodies of the present invention can be used in combination with monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, short chain Fvs (scFV), single chain antibodies, Fab fragments, F (ab ') fragments, disulfide- And anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of such antibodies, and the like.

The antibody of the present invention binds to the PRRSV-derived antigen protein to form an antigen-antibody complex.

According to another aspect of the present invention, the present invention provides a PRRSV diagnostic method comprising the steps of:

(a) contacting a sample with the bioprobe of the present invention;

(b) measuring the degree of light scattering of the reaction product of the bio-probe and the sample; And

(c) analyzing the presence or absence of PRRSV in the sample from the measurement result of step (b).

In the present invention, the antibody used for the diagnosis of PRRSV has a form bound to a nanomaterial, so that the size of the result of the immunoagglutination reaction by the antigen-antibody binding is larger than that of the antigen-antibody complex without the nanomaterial . When the size of the result of the immunoagglutination reaction is increased, since the intensity of the scattered light scattered from the immunoglobulin reaction product is also amplified when the light is irradiated to the result of the immunoagglutination reaction, the presence or absence of PRRSV in the sample can be easily determined using the bioprobe of the present invention have.

As used herein, the term " sample " refers to a biological sample which is a tissue, cell, urine, saliva, whole blood, serum, plasma, tissue autopsy sample (brain, skin, lymph node, spinal cord, etc.), cell culture supernatant, Bacterial expression systems, and the like. These samples may be reacted with the bioprobe of the present invention without manipulation or manipulation so that the presence or absence of a pathogen may be confirmed.

The antibody linked to the nanomaterial surface of the bioprobe of the present invention binds to the antigen protein in the sample and exhibits an immune aggregation reaction. Immunoconjugation reaction by antigen-antibody binding can be determined by irradiating the reaction product with light and measuring scattered light scattered therefrom.

In the present invention, the measurement of the degree of light scattering can be performed using various optical measuring devices known in the art.

According to a preferred embodiment of the present invention, a sample to be measured is first applied to a bioprobe to which an antibody is not bound, reacted, and then the light scattering degree is measured after the light is irradiated. After the reaction, the light is irradiated and the light scattering degree is measured. Preferably, the light scattering degree is measured at a wavelength of 380 nm.

The final measurement value is calculated by subtracting the measured value derived from the bioprobe to which the antibody is bound from the measured value derived from the non-antibody bound bioprobes. If the final measured value is 100 or more, the result is positive. If the final measured value is less than 100, it is judged as negative to analyze the pathogen in the sample.

The features and advantages of the present invention are summarized as follows:

(a) The present invention provides a bioprobe for PRRSV detection.

(b) The present invention provides a method for diagnosing PRRSV using the above-mentioned bioprobe.

(c) Using the bioprobe of the present invention, the presence of PRRSV and the presence or absence of PRRSV can be quickly measured within 10 minutes from a small amount of sample.

FIG. 1 is a graph showing the result of SDS-PAGE electrophoresis after expressing and purifying a recombinant protein for PRRSV US type NP.
2 is a schematic view of a process of manufacturing a bio-probe.
FIG. 3 shows the result of SEM photographing the surface of the glass fiber to which the nanomaterial bonded with the glass fiber and the antibody is bonded. (a) 500 times, (b) 2,000 times, and (c) 4,000 times.
FIG. 4 shows the result of measuring the specificity of the light scattering method for PRRSV.
Figure 5 shows the results of measuring the specificity of the RT-PCR method for PRRSV.
FIG. 6 shows the results of measuring the specificity of ELISA for PRRSV.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Example

Example 1: Porcine genital respiratory syndrome virus (PRRSV) rTEV US NP antigen production

1-1. Expression of antigen protein

PRRSV PL96-1 was purchased from the National Veterinary Research and Quarantine Service. Recombinant E. coli (p-ET TEV PRRSV US NP) was prepared by RT-PCR of the gene coding for NP in PRRSV viral RNA and the amplified DNA was ligated with pET TEV vector. To prepare the recombinant protein PRRSV r-TEV US NP to be used as an antigen for PRRSV, the strain p-ET TEV PRRSV US NP was inoculated into 25 ml of LB medium containing ampicillin and cultured at 37 ° C for 12 hours with shaking at 250 rpm. 1 L of ampicillin-containing LB medium was inoculated with 25 ml of shaking culture medium, cultured at 37 ° C and 250 rpm in shaking incubator for 2 hours 30 minutes -3 hours 30 minutes, and 1 ml IPTG 1 ml at OD ₆₀₀ value of 0.6 Was added to the culture. After addition of IPTG, recombinant protein expression was induced by incubation at 37 ° C and 250 rpm for 3 hours. The culture was centrifuged at 8.degree. C. and 8.000 rpm for 20 minutes. The supernatant was discarded and the pellet was suspended in 10-20 ml of PBS. After centrifugation at 4 ° C and 12,000 rpm for 20 minutes, the cells were washed, and the precipitated cells were stored at -20 ° C. until use. Some pellets were taken and electrophoresed on 14% SDS-PAGE to identify the expressed protein (17.1 KDa) (Fig. 1).

1-2. Purification of antigen proteins

The cell pellet (1L basis) 10 such that the binding buffer, 1 mg / ml was suspended in _{(20 mM NaH 2 PO 4,} 500 mM NaCl, 10 mM imidazole, pH 7.4) of 20 ml (1/50 volume) mg / ml egg white lysozyme was added, and the mixture was reacted on ice for 30 minutes. Then, cells were disrupted by ultrasonication. The disrupted cell suspension was centrifuged at 13,000 rpm. After centrifugation at 4 ° C for 20 minutes, the supernatant was stored at 4 ° C. To purify the protein using 5 ml of HiTrap chelating HP column, the column was washed with 20 mL of distilled water. 10 ml of 0.1 M NiSO ₄ buffer was loaded onto the column, then washed with 20 ml of distilled water, and 25 ml of 1X binding buffer was loaded on the column to equilibrate. A 20 mL sample to the column 2 ml / one minutes, and then loaded at a rate of, 1X wash buffer _{(20 mM NaH 2 PO 4,} 500 mM NaCl, 20-60 mM imidazole, pH 7.4) imidazole concentrations (1 to 30 mL 20 mM twice, 40 mM twice, 60 mM three times). To a 1X elution buffer _{(20 mM NaH 2 PO 4,} 500 mM NaCl, 500 mM, pH 7.4 imidazole) loaded on the column and eluted by 1.5 ml of each fraction to give the tube. The protein content of the pulmonary tuberculosis was measured by BCA method, and the fraction of 200 μg / ml or more was recovered and pooled, followed by electrophoresis on 14% SDS-PAGE to identify a protein of 17.1 kDa. 0.05% sodium azide was added to the purified protein and stored at 4 ° C.

Example 2: Preparation of PRRSV antibody

The PRRSV rTEV US NP recombinant protein prepared by the above method was used as an immunogen to prepare an antibody. First, 200 μl of PRRSV rTEV US NP recombinant protein (0.3 mg / ml) and 200 μl of Freund's Adjuvant were mixed and immunized with Balb / C mouse abdominal cavity four times at intervals of 2 weeks. Blood was collected from the mice one week after the 4th immunization, and the serum was isolated and subjected to an indirect ELISA. The final immunization was performed by intraperitoneal injection of 200 μl of PRRSV rTEV US NP recombinant protein (0.3 mg / ml). Four days after the last immunization, lympocytes were isolated from immunized mice, and these cells were fused with myeloma cells SP2 / 0 Ag14 (ATCC, USA) using PEG method to prepare hybridoma cells.

Hybridoma cells were screened to select clones that specifically respond to the target antigen (PRRSV rTEV US NP recombinant protein). Hybridoma cell culture supernatant was reacted with the target antigen (PRRSV rTEV US NP recombinant protein, 0.3 μg / ml), and indirect ELISA and immunofluorescence assay were performed to detect cells that specifically react with the target antigen Were first screened. The hybridoma cell culture supernatant selected in the first screening was reacted with the target antigen (PRRSV rTEV US NP recombinant protein, 0.3 μg / ml) and subjected to indirect ELISA to identify cells that specifically respond to the PRRSV rTEV US NP antigen Were secondarily screened. Antibodies were obtained from selected hybridoma cells in secondary screening and IgG antibodies were screened using a single antibody isotyping reagent (Sigma, USA).

Example 3: Preparation of a bioprobe

Bioprobe is a binding complex between antibody and nanoparticle (latex bead).

1) Preparation of antibody: Prepared by mixing 38 μg of the selected antibody and 1 ml of PBS.

2) Preparation of nanoparticles: 5 .mu.l of the stock solution (120 nm carboxyl polystyrene beads, bangs laboratories) and 0.995 ml of PBS were mixed at a concentration of 0.05%, and centrifuged at 12,000 rpm for 15 minutes. And washed. The suspension was suspended in MES buffer, and 10 mg of EDC was added thereto, followed by reaction for 15 minutes. After completion of the reaction, the supernatant was discarded by centrifugation under the same conditions, washed twice with PBS, and suspended again in PBS.

3) Preparation of the complex: The solution prepared in step 1) was mixed with the result of step 2) and reacted at room temperature for 3 hours using a rotator.

4) Blocking and washing: To remove the unreacted antibody and to inactivate the chemicals, the supernatant was discarded to remove the unreacted antibody. 1 mL of hydroxilamine was added to the reaction solution for 30 minutes, and the reaction was allowed to proceed at 12,000 rpm for 15 minutes After centrifugation, the supernatant was removed and 995 μL of PBS was added. The completed bioprobes were stored at 4 < 0 > C.

Example 4: Drying to maintain bio-probe stability

The bio-probe solution has a disadvantage that its activity decreases over time. (Sigma), 0.01% Tween (Sigma), and 0.01% Triton (Sigma) were added to a glass fiber pad (marck) in order to overcome this disadvantage and to secure stability. , And 10 μl of the bioprobe solution was placed in a glass fiber pad having a diameter of 5 mm and dried at 55 ° C for 30 minutes. Sucrose and trehalose help stabilize the low-concentration antibody when stored in a pad and help release the reactant from the pad after the reaction is complete on the pad. Actually, when the bio-probe is dried on the pad without adding the above four chemicals, it takes a long time for the bio-probe to be released from the pad (data not shown). Surfactants are also used to reduce the nonspecific response of antigen-antibody reactions. SEM photographs of the glass fiber pads before, after and after sample loading are shown in Figs. 4A-C.

Example 5: Detection method using a dry glass fiber pad

The degree of scattering of light according to the antigen-antibody aggregation reaction was measured by the following steps.

a) Insert a dry glass fiber pad with a bioprobe that is not coupled to the antibody into the chip injection port.

b) When 50 μl of the sample to be detected is loaded into the injection port 1 and the sample is filled up to the light scattering measurement section 3 through the reaction channel 2 (taking about 3-5 seconds), light scattering ) Apparatus, and the light scattering degree of the light scattering measuring unit 3 is measured four times in total at a wavelength band of 380 nm, and an average value is calculated. The sample passed through the light scattering measurement unit is discharged to the discharge port 5 through the capillary force increasing channel 4.

c) Insert a dry glass fiber pad with attached antibody-bound bioprobes into the chip injection port.

d) When 50 μl of the same sample used in step c) was loaded into the injection port, and the sample was filled up to the light scattering measurement unit after passing through the reaction channel, the light scattering unit of the light scattering measurement unit was placed in the light scattering apparatus at a wavelength of 380 nm A total of four measurements are made and the average value is calculated.

e) subtracting the measured value of step b) from the value measured in step d) to calculate the final measured value. If the final measured value is 100 or more, it is positive. If it is less than 100, it is judged as negative.

Example 6: Comparison of detection limits

The detection limit of the light scattering method using the glass fiber pad prepared by the above method was compared with the RT-PCR diagnostic method. RT-PCR was performed using the product VDX-3024 (PRRSV ORF7 RT-PCR) manufactured by the applicant of the present invention. Virus RNA was extracted using QIAGEN KIT (7 concentrations diluted 1/10 from virus stock). (20 μl) of the RT-PCR product and 5 μl of the extracted virus were mixed and placed in a PCR apparatus (TAKARA). The reaction was carried out at 45 ° C. for 30 minutes and at 95 ° C. for 5 minutes and then at 94 ° C. for 20 seconds and at 55 ° C. 20 seconds and 72 ° C for 30 seconds, followed by reaction at 72 ° C for 5 minutes. After 5 μl of the PCR reaction was added to 1.5% agarose gel, electrophoresis was performed, and the result was analyzed using GELDOC (BIORAD).

Sandwich ELISA was performed by immobilizing the antibody prepared in Example 2 on an ELISA plate. First, the antibody was dispensed on an ELISA plate at a concentration of 1 μg / ml, fixed at 37 ° C for 1 hour, and then washed three times with 0.05 M PBST. Plates were coated with 1% PVP (Sigma), washed three times with 0.05 M PBST, diluted virus was added to the concentration to be measured, reacted at 37 ° C for 1 hour, and washed three times with 0.05 M PBST . HRP was coupled (200 ng / ml) to an antibody, such as a fixed antibody, at 37 ° C for 1 hour and then washed three times with 0.05 M PBST. TMB (MOSS) was added to induce color development, and then the reaction was stopped and the absorbance at 450 nm was measured. The S / N ratio was calculated by dividing the OD value of the sample by the OD value of the negative control reaction in which PBS was added in place of the virus.

As a result, the light scattering method of the present invention showed a detection limit of about 10 times lower than the RT-PCR diagnostic method and a detection limit of about 1,000 times higher than the ELISA diagnostic method (Table 1).

- Test method Light scattering method Sandwich ELISA RT-PCR S / N ratio Positive / negative S / N ratio Positive / negative Positive / negative Virus concentration
(TCID ₅₀ / ml) 1,000 13.95 positivity 2.92 positivity positivity 100 11.90 positivity 1.65 positivity positivity 10 10.68 positivity 1.08 voice positivity One 8.54 positivity 1.05 voice positivity 0.1 7.35 positivity 0.75 voice positivity 0.01 0.97 voice 0.76 voice positivity 0.001 0.90 voice 0.70 voice voice PBS     1.00 voice    1.00 voice voice

Example 7 Comparison of Sensitivity and Specificity with RT-PCR Diagnostic Methods

The sensitivity and specificity of the light scattering method using glass fiber pads prepared by the above method were compared with the RT-PCR method, which is a definite diagnostic method of PRRSV US. The measurement sensitivity was calculated by dividing the number of samples determined as positive by the number of samples determined as positive and the number of samples showing the false negatives. The measurement specificity was determined by comparing the number of samples identified by speech with the number of samples identified by speech and false positive And the number of samples was added.

Five samples judged to be positive by RT-PCR and 45 samples judged to be negative were applied to the glass fiber pad of the present invention produced by the above method. As a result, And three out of 45 speech samples were judged to be positive. There were 0 false positive samples and 3 false positive samples. The sensitivity and specificity of the diagnostic method of the present invention as compared with the RT-PCR method were 100% and 93%, respectively (Table 2).

Comparison with RT-PCR method PRRSV US Diagnosis Light scattering method Measurement sensitivity
(Positive / (positive + false negative) 100% positivity voice synthesis RT-PCR positivity 5 0 5 Measurement specificity
(Voice / (voice + false positive) 93% voice 3 42 45 synthesis 8 42 50

Example 8 Confirmation of Specificity of Light Scattering Method, RT-PCR and ELISA Method

PRRSV US type, PRRSV EU type, Japanese encephalitis virus (JEV), encephalomyocarditis virus (JEV), and the like were used to confirm the specificity of the light scattering method using the glass fiber pad produced by the above method. (Eg, EMCV), Classical swine fever virus (CSFV) LOM, Swine influenza H1N2, Adenovirus (ADV), Porcine parvovirus (PPV), Porcine circovirus type 2 , Lung tissue, blood and semen as samples. The titers of the viruses are shown in Table 3, and diluted 1/10 in actual experiments.

Virus name Potency PRRSV US 10 ³ TCID ₅₀ / ml Titer PRRSV EU 10 ² TCID ₅₀ / ml Titer JEV 10 ⁶ TCID ₅₀ / ml Titer EMCV 10 ^5.1 TCID ₅₀ / ml Titer CSFV 10 ⁵ TCID ₅₀ / ml Titer SIV H1N2 10 ⁶ TCID ₅₀ / ml Titer ADV 10 ^7.5 TCID ₅₀ / ml Titer PPV 10 ^6.1 TCID ₅₀ / ml TITER PCV2 10 ⁵ TCID ₅₀ / ml Titer

The light intensity of each sample was measured and the intensity of light was less than 100 in JEV, EMCV, CSFV LOM, SIV H1N2, ADV, PPV, PCV2, lung tissue, Showed a strong light intensity of about 350 in the US type and about 150 in the PRRSV EU type, confirming that the glass-fiber pads to which the antibodies of the present invention bound had high specificity for the PRRSV US type (FIG. 5).

The specificity of RT-PCR for PRRSV was 20 or less in JEV, EMCV, CSFV LOM, SIV H1N2, ADV, PPV, PCV2, lung tissue, blood and semen samples, The intensity of PRRSV US and EU were about 100 and 80, respectively, and the specificity of PRRSV detection by RT-PCR was high (Fig. 5). The intensity was obtained by electrophoresing the RT-PCR result on an agarose gel and converting the band intensity from the resultant image using the image J program.

On the other hand, the specificity of the ELISA method was measured. As a result, the reactivity was low for other virus samples and outdoor samples in addition to PRRSV US type samples (FIG. 6).

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

<110> MEDIAN Diagnostics Inc. <120> A Bio Probe for Detecting Porcine Reproductive and Respiratory          Syndrome Virus and Method for Diagnosing PRRSV Using the Same <130> PP120500 <160> 4 <170> Kopatentin 2.0 <210> 1 <211> 372 <212> DNA <213> PRRSV US type NP antigen nucleotides <400> 1 atgccaaata acaacggcaa gcagcagaag agaaagaagg gggatggcca gccagtcaat 60 cagctgtgcc agatgctggg taagatcatc gctcagcaaa accagtccag aggcaaggga 120 ccgggaaaga aaaataagaa gaaaaacccg gagaagcccc attttcctct agcgactgaa 180 gatgatgtca gacatcactt tacccctagt gagcggcaat tgtgtctgtc gtcaatccag 240 accgccttta atcaaggcgc tgggacttgc accctgtcag attcagggag gataagttac 300 actgtggagt ttagtttgcc tacgcatcat actgtgcgcc tgatccgcgt cacagcgtca 360 ccctcagcat ga 372 <210> 2 <211> 123 <212> PRT <213> PRRSV US type NP antigen amino acids <400> 2 Met Pro Asn Asn Asn Gly Lys Gln Gln Lys Arg Lys Lys Gly Asp Gly   1 5 10 15 Gln Pro Val Asn Gln Leu Cys Gln Met Leu Gly Lys Ile Ile Ala Gln              20 25 30 Gln Asn Gln Ser Arg Gly Lys Gly Pro Gly Lys Lys Asn Lys Lys Lys          35 40 45 Asn Pro Glu Lys Pro His Phe Pro Leu Ala Thr Glu Asp Asp Val Arg      50 55 60 His His Phe Thr Pro Ser Glu Arg Gln Leu Cys Leu Ser Ser Ile Gln  65 70 75 80 Thr Ala Phe Asn Gln Gly Ala Gly Thr Cys Thr Leu Ser Asp Ser Gly                  85 90 95 Arg Ile Ser Tyr Thr Val Glu Phe Ser Leu Pro Thr His His Thr Val             100 105 110 Arg Leu Ile Arg Val Thr Ala Ser Pro Ser Ala         115 120 <210> 3 <211> 387 <212> DNA <213> PRRSV EU type NP antigen nucleotides <400> 3 atggccggta aaaaccagag ccagaagaaa aagaaaagta cagctccgat ggggaatggc 60 cagccagtca atcaactgtg ccagttgctg ggtgcaatga taaagtccca gcgccagcaa 120 cctaggggag gacaggccaa aaagaaaaag cctgagaagc cacattttcc cctggctgct 180 gaagatgaca tccggcacca cctcacccag actgaacgct ccctctgctt gcaatcgatc 240 cagacggctt tcaatcaagg cgcaggaact gcgtcgcttt catccagcgg gaaggtcagt 300 tttcaggttg agtttatgct gccggttgct catacagtgc gcctgattcg cgtgacttct 360 acatccgcca gtcagggtgc aagttaa 387 <210> 4 <211> 128 <212> PRT <213> PRRSV EU type NP antigen amino acids <400> 4 Met Ala Gly Lys Asn Gln Ser Gln Lys Lys Lys Lys Ser Thr Ala Pro   1 5 10 15 Met Gly Asn Gly Gln Pro Val Asn Gln Leu Cys Gln Leu Leu Gly Ala              20 25 30 Met Ile Lys Ser Gln Arg Gln Gln Pro Arg Gly Gly Gln Ala Lys Lys          35 40 45 Lys Lys Pro Glu Lys Pro His Phe Pro Leu Ala Ala Glu Asp Asp Ile      50 55 60 Arg His His Leu Thr Gln Thr Glu Arg Ser Leu Cys Leu Gln Ser Ile  65 70 75 80 Gln Thr Ala Phe Asn Gln Gly Ala Gly Thr Ala Ser Leu Ser Ser Ser                  85 90 95 Gly Lys Val Ser Phe Gln Val Glu Phe Met Leu Pro Val Ala His Thr             100 105 110 Val Arg Leu Ile Arg Val Thr Ser Thr Ser Ala Ser Gln Gly Ala Ser         115 120 125

Claims (11)

Bioprobes for detection of Porcine Reproductive and Respiratory Syndrome Virus including:
(a) a nanomaterial;
(b) an antibody that specifically binds to an antigen of a porcine reproductive and respiratory syndrome virus covalently linked to the surface of the nanomaterial; And
(c) glass fiber as a solid substrate whose surface is modified with the nanomaterial to which the antibody is bound.
The bio-probe according to claim 1, wherein the porcine reproductive / respiratory syndrome virus is of the EU type (European type) or the US type (American type).
3. The bio-probe according to claim 2, wherein the porcine reproductive / respiratory syndrome virus is of the US type.
The bio-probe according to claim 1, wherein the nanomaterial is polystyrene nanoparticles.
The bio-probe according to claim 1, wherein the glass fiber is borosilicate glass fiber.
The bio-probe according to claim 1, wherein the solid substrate is surface-modified with the nanomaterial to which the antibody is bound using sugar and a surfactant.
2. The bio-probe according to claim 1, wherein the antigen of the porcine reproductive-respiratory syndrome virus is a nucleocapsid protein of a porcine reproductive-respiratory syndrome virus.
8. The bioprobe according to claim 7, wherein the nucleocapsid protein of the porcine reproductive / respiratory syndrome virus has the amino acid sequence of SEQ ID NO: 2.
A method for diagnosing porcine reproductive and respiratory syndrome virus comprising the steps of:
(a) contacting a sample with the bioprobe of any one of claims 1 to 8;
(b) measuring the degree of light scattering of the reaction product of the bio-probe and the sample; And
(c) analyzing the presence or absence of virus in the sample of the genital respiratory syndrome in the sample from the measurement result of step (b).
10. The method according to claim 9, wherein the porcine reproductive / respiratory syndrome virus is of European type or US type.
11. The method of claim 10, wherein the porcine reproductive tract respiratory syndrome virus is of the US type.

Images